|
Market Closed -
Nasdaq
16:00:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 9.340 USD | -2.61% |
|
+3.78% | +14.18% |
| 10-27 | Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating | MT |
| 10-23 | ORIC Pharmaceuticals, Inc. - Special Call |
Company Valuation: ORIC Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 578.9 | 264.8 | 501.9 | 569.5 | 796.6 | 994 | - | - |
| Change | - | -54.26% | 89.55% | 13.47% | 39.89% | 24.78% | - | - |
| Enterprise Value (EV) | 578.9 | 264.8 | 266.8 | 569.5 | 751 | 994 | 994 | 994 |
| Change | - | -54.26% | 0.78% | 113.42% | 31.87% | 32.37% | 0% | 0% |
| P/E | -7.1x | -2.62x | -4.69x | -4.41x | -5.56x | -6.31x | -5.63x | -4.93x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 0.4x | 0.66x | 0.3x | -1.83x | -0.5x | -0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 361x |
| EV / Revenue | - | - | - | - | - | - | - | 361x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -6.16x | -6x | -6.95x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -5.55x | -4.71x | -4.1x |
| EV / FCF | -0x | -0x | -0x | -0x | -0x | -7.39x | -5.99x | -4.96x |
| FCF Yield | -10.4% | -29.2% | -17.2% | -20% | -14% | -13.5% | -16.7% | -20.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.07 | -2.25 | -1.96 | -1.83 | -1.47 | -1.521 | -1.703 | -1.947 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 2.757 |
| EBITDA 1 | -77.97 | -90.8 | -109.7 | -141.8 | -141.8 | -161.4 | -165.6 | -143 |
| EBIT 1 | -78.87 | -91.77 | -110.8 | -142.9 | -143 | -179 | -211.1 | -242.3 |
| Net income 1 | -78.72 | -89.12 | -100.7 | -127.8 | -129.5 | -166.2 | -201.4 | -254.1 |
| Net Debt | - | - | -235 | - | -45.67 | - | - | - |
| Reference price 2 | 14.700 | 5.890 | 9.200 | 8.070 | 8.180 | 9.590 | 9.590 | 9.590 |
| Nbr of stocks (in thousands) | 39,382 | 44,953 | 54,552 | 70,567 | 97,389 | 103,653 | - | - |
| Announcement Date | 3/21/22 | 3/16/23 | 3/11/24 | 2/18/25 | 2/23/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.31x | - | - | -.--% | 994M | |
| 16.04x | 6.01x | 11.53x | 1.86% | 60.57B | |
| 38x | 6.73x | 20.1x | 0.85% | 55.51B | |
| 29.64x | 7.94x | 26.66x | 0.05% | 55.22B | |
| 34.27x | 3.27x | 14.1x | -.--% | 43.27B | |
| 46.82x | 5.37x | 29.4x | -.--% | 40.36B | |
| -20.16x | 195.48x | -21.51x | -.--% | 41.63B | |
| 45.18x | 8.03x | 26.9x | -.--% | 33.29B | |
| 31.71x | 8.03x | 20.88x | 0.41% | 32.27B | |
| -65.46x | 12.04x | -67.36x | -.--% | 22.91B | |
| Average | 14.98x | 28.10x | 6.74x | 0.32% | 38.6B | |
| Weighted average by Cap. | 21.43x | 27.20x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORIC Stock
- Valuation ORIC Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
